Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.
作者信息
Demetris A J, Banner B, Fung J, Shapiro R, Jordan M, Starzl T E
机构信息
Department of Pathology, Presbyterian University Hospital, Pittsburgh, Pennsylvania 15213.
出版信息
Transplant Proc. 1991 Feb;23(1 Pt 2):944-6.
Abstract
摘要
相似文献
1
Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.
Transplant Proc. 1991 Feb;23(1 Pt 2):944-6.
2
A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection.
Transplant Proc. 1990 Aug;22(4):1638-41.
3
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
Transplant Proc. 1991 Feb;23(1 Pt 1):14-21.
4
Pathologic observations in human allograft recipients treated with FK 506.
Transplant Proc. 1990 Feb;22(1):25-34.
5
Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation.
Transplant Proc. 1990 Dec;22(6):2485-6.
6
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.
Transplant Proc. 1991 Feb;23(1 Pt 1):396-9.
7
A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression.
Transplant Proc. 1996 Jun;28(3):1335-7.
8
Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression.
Transplant Proc. 1990 Aug;22(4):1655-7.
9
Reversal of accelerated renal allograft rejection with FK 506.
Clin Transplant. 1997 Aug;11(4):251-4.
10
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.
Transplant Proc. 1987 Oct;19(5 Suppl 6):57-61.
引用本文的文献
1
Pediatric renal transplantation under tacrolimus-based immunosuppression.
Transplantation. 1999 Jan 27;67(2):299-303. doi: 10.1097/00007890-199901270-00020.
2
3
Tacrolimus in pediatric renal transplantation.
Transplantation. 1996 Dec 27;62(12):1752-8. doi: 10.1097/00007890-199612270-00010.
4
The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience.
Clin Transpl. 1995:199-205.
5
Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.
J Clin Invest. 1996 Jun 1;97(11):2433-9. doi: 10.1172/JCI118690.
6
The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.
Am J Surg Pathol. 1993 Jan;17(1):60-8. doi: 10.1097/00000478-199301000-00007.
7
Renal transplantation at the University of Pittsburgh: the impact of FK506.
Clin Transpl. 1994:229-36.
8
A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.
Transplant Proc. 1995 Feb;27(1):814-7.
9
A prospective randomized trial of FK506-based immunosuppression after renal transplantation.
Transplantation. 1995 Feb 27;59(4):485-90. doi: 10.1097/00007890-199559040-00007.
10
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.
Drugs. 1993 Oct;46(4):746-94. doi: 10.2165/00003495-199346040-00009.
本文引用的文献
1
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
Transplant Proc. 1990 Feb;22(1):6-12.
2
Pathologic observations in human allograft recipients treated with FK 506.
Transplant Proc. 1990 Feb;22(1):25-34.
3
Early trials with FK 506 as primary treatment in liver transplantation.
Transplant Proc. 1990 Feb;22(1):13-6.
Zotero 插件